# EDGAR Filing Document

**Accession Number:** 0001596062
**File Stem:** 0001104659-23-027193
**Filing Date:** 2023-3
**Character Count:** 3186
**Document Hash:** a38b3f10bcc5701ec125f7cfe5db5906
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-027193.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001104659-23-027193

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**EFFECTIVENESS DATE**: 20230301

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q BioMed Inc.
- **CENTRAL INDEX KEY:** 0001596062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464013793
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55535
- **FILM NUMBER:** 23692138

**BUSINESS ADDRESS:**
- **STREET 1:** 366 MADISON AVE.
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-588-0022

**MAIL ADDRESS:**
- **STREET 1:** 366 MADISON AVE.
- **STREET 2:** 3RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISMO Tech Solutions, Inc.
- **DATE OF NAME CHANGE:** 20140107

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

**SEC File Number 000-55535**

⌧ Form 10-K ◻ Form 20-F ◻ Form 11-K ◻ Form 10-Q ◻ Form 10-D ◻ Form N-SAR ◻ Form N-CSR

For Period Ended: <u>November 30, 2022</u>

**PART I: REGISTRANT INFORMATION**

Full Name of Registrant: Q BioMed Inc.

Address of Principal Executive Office:

**c/o Ortoli Rosenstadt LLP**

**366 Madison Avenue, 3<sup>rd</sup> Floor**

**<u>New York, NY 10017</u>**

**PART II: RULES 12B-25(B) AND (C)**

It is anticipated that the subject Annual Report on Form 10-K will be filed as soon as feasible.

**PART III: NARRATIVE**

The Registrant has not completed its Annual Report on Form 10-k for the period ended November 30, 2022, due to administrative delays.

**PART IV: OTHER INFORMATION**

(1) Name and telephone number of person(s) to contact in regard to this notification

Denis Corin: 212-588-0022

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

⌧ YES ◻ NO

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

◻ YES ⌧ NO

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Q BioMed Inc. has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Q BioMed Inc.** | **Q BioMed Inc.** |
| Dated: March 1, 2023 | By: | /s/ Denis Corin |
|  |  | Denis Corin |
|  |  | Chief Executive Officer |

---